Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography‐tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia
Open Access
- 31 January 2024
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 112 (6) , 879-888
Abstract
Objectives: Midostaurin is an oral multitargeted tyrosine kinase inhibitor for the treatment of acute myeloid leukemia (AML). Therapeutic drug monitoring of midostaurin may support its safe use when suspecting toxicity or combined with strong CYP3A4 inhibitors. Methods: A stable isotope dilution liquid chromatography-tandem mass spectrometry method was developed and validated for the determination and quantification of midostaurin in human plasma and serum. Midostaurin serum concentrations were analyzed in 12 patients with FMS-like tyrosine kinase 3 (FLT3)-mutated AML during induction chemotherapy with cytarabine, daunorubicin, and midostaurin. Posaconazole was used as prophylaxis of invasive fungal infections. Results: Linear quantification of midostaurin was demonstrated across a concentration range of 0.01-8.00 mg/L. Inter- and intraday imprecisions of the proposed method were well within +/- 10%. Venous blood samples were taken in nine and three patients in the first and second cycle of induction chemotherapy. Median (range) midostaurin serum concentration was 7.9 mg/L (1.5-26.1 mg/L) as determined in 37 independent serum specimens. Conclusion: In a real-life cohort of AML patients, interindividual variability in midostaurin serum concentrations was high, highlighting issues concerning optimal drug dosing in AML patients. A personalized dosage approach may maximize the safety of midostaurin. Prospective studies and standardization of analytical methods to support such an approach are needed.Keywords
This publication has 26 references indexed in Scilit:
- Liquid chromatography–tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosisJournal of Chromatography B, 2014
- Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteersCancer Chemotherapy and Pharmacology, 2013
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3Journal of Clinical Oncology, 2010
- Dose‐ and Time‐Dependent Pharmacokinetics of Midostaurin in Patients With Diabetes MellitusThe Journal of Clinical Pharmacology, 2008
- A Mechanism-Based Population Pharmacokinetic Model for Characterizing Time-Dependent Pharmacokinetics of Midostaurin and its Metabolites in Human SubjectsClinical Pharmacokinetics, 2008
- A highly sensitive method for the detection of PKC412 (CGP41251) and its metabolites by high-performance liquid chromatographyJournal of Pharmacological and Toxicological Methods, 2007
- Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with NeutropeniaNew England Journal of Medicine, 2007
- Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitorsBlood, 2006
- Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover studyEuropean Journal of Pharmaceutical Sciences, 2004
- Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase CJournal of Clinical Oncology, 2001